JC
REGN icon

JBF Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

JBF Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Hold
5,000
– – 0.41% 22
2026
Q1 		$3.86M Hold
5,000
– – 0.57% 21
2025
Q4 		$3.86M Buy
+5,000
New +$3.4M 0.56% 19

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JBF Capital's REGN Position: Q2 2026 in Review

JBF Capital held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 5,000 shares worth $3.12M. The position accounts for 0.41% of the portfolio, ranked #22.

JBF Capital first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.86M in Q1 2026. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • JBF Capital held 5,000 shares of Regeneron Pharmaceuticals worth $3.12M as of Q2 2026.
  • JBF Capital left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.41% of JBF Capital's portfolio in Q2 2026, its #22 holding.
  • JBF Capital first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • JBF Capital's Regeneron Pharmaceuticals position peaked at $3.86M in Q1 2026.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on JBF Capital's 13F filing for Q2 2026, filed 13 Aug 2026.